A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2019
Price : $35 *
At a glance
- Drugs IONIS-GCGRRx (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Ionis Pharmaceuticals; Isis Pharmaceuticals
- 14 Feb 2019 Results evaluating the safety and efficacy of IONIS-GCGRRx from three phase 2 (NCT01885260, NCT02583919, NCT02824003) published in the Diabetes Care.
- 24 Jan 2015 Planned number of patients changed from 72 to 77.
- 24 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History